BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Brautbar A, Leary E, Rasmussen K, Wilson DP, Steiner RD, Virani S. Genetics of familial hypercholesterolemia. Curr Atheroscler Rep 2015;17:491. [PMID: 25712136 DOI: 10.1007/s11883-015-0491-z] [Cited by in Crossref: 50] [Cited by in F6Publishing: 38] [Article Influence: 7.1] [Reference Citation Analysis]
Number Citing Articles
1 Shim YH, Ock JW, Kim YJ, Kim Y, Kim SY, Kang D. Association between Heavy Metals, Bisphenol A, Volatile Organic Compounds and Phthalates and Metabolic Syndrome. Int J Environ Res Public Health 2019;16:E671. [PMID: 30823556 DOI: 10.3390/ijerph16040671] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
2 Saavedra YGL, Dufour R, Baass A. Familial hypercholesterolemia: PCSK9 InsLEU genetic variant and prediabetes/diabetes risk. Journal of Clinical Lipidology 2015;9:786-793.e1. [DOI: 10.1016/j.jacl.2015.08.005] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 4.6] [Reference Citation Analysis]
3 Cephus CE, Qureshi AM, Sexson-Tejtel SK, Goss JA, Moodie DS. Liver Transplantation for HoFH in Children: Single Center Experience. Congenit Heart Dis 2015;10:520-8. [PMID: 26556546 DOI: 10.1111/chd.12301] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
4 Oberemok VV, Laikova KV, Repetskaya AI, Kenyo IM, Gorlov MV, Kasich IN, Krasnodubets AM, Gal'chinsky NV, Fomochkina II, Zaitsev AS, Bekirova VV, Seidosmanova EE, Dydik KI, Meshcheryakova AO, Nazarov SA, Smagliy NN, Chelengerova EL, Kulanova AA, Deri K, Subbotkin MV, Useinov RZ, Shumskykh MN, Kubyshkin AV. A Half-Century History of Applications of Antisense Oligonucleotides in Medicine, Agriculture and Forestry: We Should Continue the Journey. Molecules 2018;23:E1302. [PMID: 29844255 DOI: 10.3390/molecules23061302] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
5 Ajufo E, Cuchel M. Recognition, diagnosis and treatment of homozygous familial hypercholesterolemia. Expert Opinion on Orphan Drugs 2017;5:933-43. [DOI: 10.1080/21678707.2017.1394841] [Reference Citation Analysis]
6 Lunegova OS, Mirrakhimov AE, Hodzhiboboev E, Bektasheva EE, Neronova KV, Toktomamatov UM, Zakirov U, Asanbaev A, Arapova RA, Abilova SS, Kerimkulova AS, Mirrakhimov EM. The frequency of familial hypercholesterolemia amongst patients in the outpatient clinic of the tertiary specialized cardiology center in Kyrgyzstan. Atheroscler Suppl 2019;36:1-5. [PMID: 30876526 DOI: 10.1016/j.atherosclerosissup.2019.01.001] [Reference Citation Analysis]
7 Jones PJH, Shamloo M, MacKay DS, Rideout TC, Myrie SB, Plat J, Roullet JB, Baer DJ, Calkins KL, Davis HR, Barton Duell P, Ginsberg H, Gylling H, Jenkins D, Lütjohann D, Moghadasian M, Moreau RA, Mymin D, Ostlund RE Jr, Ras RT, Ochoa Reparaz J, Trautwein EA, Turley S, Vanmierlo T, Weingärtner O. Progress and perspectives in plant sterol and plant stanol research. Nutr Rev 2018;76:725-46. [PMID: 30101294 DOI: 10.1093/nutrit/nuy032] [Cited by in Crossref: 23] [Cited by in F6Publishing: 17] [Article Influence: 7.7] [Reference Citation Analysis]
8 Jia X, Liu J, Mehta A, Ballantyne CM, Virani SS. Lipid-Lowering Biotechnological Drugs: from Monoclonal Antibodies to Antisense Therapies-a Clinical Perspective. Cardiovasc Drugs Ther 2020. [PMID: 32997212 DOI: 10.1007/s10557-020-07082-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
9 Rizos CV, Athyros V, Bilianou E, Chrousos G, Garoufi A, Kolovou G, Kotsis V, Rallidis L, Skalidis E, Skoumas I, Tziomalos K, Liberopoulos EN. An insight into familial hypercholesterolemia in Greece: rationale and design of the Hellenic Familial Hypercholesterolemia Registry (HELLAS-FH). Hormones (Athens) 2017;16:306-12. [PMID: 30091117 DOI: 10.1007/BF03401525] [Cited by in Crossref: 5] [Article Influence: 1.3] [Reference Citation Analysis]
10 Vinson A, Guerra L, Hamilton L, Wilson DP, Fnla. Reverse Cascade Screening for Familial Hypercholesterolemia. J Pediatr Nurs 2019;44:50-5. [PMID: 30683281 DOI: 10.1016/j.pedn.2018.09.011] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
11 Fogacci F, Ferri N, Toth PP, Ruscica M, Corsini A, Cicero AFG. Efficacy and Safety of Mipomersen: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. Drugs 2019;79:751-66. [PMID: 30989634 DOI: 10.1007/s40265-019-01114-z] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 9.7] [Reference Citation Analysis]
12 Deng L, Xu J, Chen W, Guo S, Steiner RD, Chen Q, Cheng Z, Xu Y, Yao B, Li X, Wang X, Deng K, Schrodi SJ, Zhang D, Xin H. Remediation of ABCG5-Linked Macrothrombocytopenia With Ezetimibe Therapy. Front Genet 2021;12:769699. [PMID: 34880906 DOI: 10.3389/fgene.2021.769699] [Reference Citation Analysis]
13 Marques P, Domingo E, Rubio A, Martinez-Hervás S, Ascaso JF, Piqueras L, Real JT, Sanz MJ. Beneficial effects of PCSK9 inhibition with alirocumab in familial hypercholesterolemia involve modulation of new immune players. Biomed Pharmacother 2022;145:112460. [PMID: 34864314 DOI: 10.1016/j.biopha.2021.112460] [Reference Citation Analysis]
14 Cao YX, Wu NQ, Sun D, Liu HH, Jin JL, Li S, Guo YL, Zhu CG, Gao Y, Dong QT, Liu G, Dong Q, Li JJ. Application of expanded genetic analysis in the diagnosis of familial hypercholesterolemia in patients with very early-onset coronary artery disease. J Transl Med 2018;16:345. [PMID: 30526649 DOI: 10.1186/s12967-018-1737-7] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 3.5] [Reference Citation Analysis]
15 Sánchez Muñoz-Torrero JF, Rivas MD, Zamorano J, Joya-Vázquez PP, de Isla LP, Padro T, Mata P, The Safeheart Investigators. Multivariate analysis for coronary heart disease in heterozygote familial hypercholesterolemia patients. Per Med 2018;15:87-92. [PMID: 29714125 DOI: 10.2217/pme-2017-0075] [Reference Citation Analysis]
16 Rizos CV, Elisaf MS, Skoumas I, Tziomalos K, Kotsis V, Rallidis L, Garoufi A, Athyros VG, Skalidis E, Kolovou G, Koutagiar I, Papagianni M, Antza C, Katsiki N, Ganotakis E, Liberopoulos EN. Characteristics and management of 1093 patients with clinical diagnosis of familial hypercholesterolemia in Greece: Data from the Hellenic Familial Hypercholesterolemia Registry (HELLAS-FH). Atherosclerosis 2018;277:308-13. [DOI: 10.1016/j.atherosclerosis.2018.08.017] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 3.8] [Reference Citation Analysis]
17 Saume A, Thiry M, Defourny J. LDLR expression in the cochlea suggests a role in endolymph homeostasis and cochlear amplification. Hear Res 2021;409:108311. [PMID: 34311268 DOI: 10.1016/j.heares.2021.108311] [Reference Citation Analysis]
18 Øyri LKL, Narverud I, Bogsrud MP, Hansson P, Leder L, Byfuglien MG, Veierød MB, Thoresen M, Ulven SM, Holven KB. Postprandial changes in gene expression of cholesterol influx and efflux mediators after intake of SFA compared with n-6 PUFA in subjects with and without familial hypercholesterolaemia: secondary outcomes of a randomised controlled trial. J Nutr Sci 2019;8:e27. [PMID: 31448116 DOI: 10.1017/jns.2019.25] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
19 Gazzola K, Reeskamp L, van den Born B. Ethnicity, lipids and cardiovascular disease: . Current Opinion in Lipidology 2017;28:225-30. [DOI: 10.1097/mol.0000000000000412] [Cited by in Crossref: 14] [Cited by in F6Publishing: 5] [Article Influence: 2.8] [Reference Citation Analysis]
20 Wright ML, Housman D, Taylor JY. A perspective for sequencing familial hypercholesterolaemia in African Americans. NPJ Genom Med 2016;1:16012. [PMID: 29263812 DOI: 10.1038/npjgenmed.2016.12] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
21 Varga VE, Lőrincz H, Zsíros N, Fülöp P, Seres I, Paragh G, Balla J, Harangi M. Impact of selective LDL apheresis on serum chemerin levels in patients with hypercholesterolemia. Lipids Health Dis 2016;15:182. [PMID: 27756331 DOI: 10.1186/s12944-016-0353-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
22 Hayat M, Kerr R, Bentley AR, Rotimi CN, Raal FJ, Ramsay M. Genetic associations between serum low LDL-cholesterol levels and variants in LDLR, APOB, PCSK9 and LDLRAP1 in African populations. PLoS One 2020;15:e0229098. [PMID: 32084179 DOI: 10.1371/journal.pone.0229098] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
23 Cabot E, Duell PB, Purnell JQ, Osborn D, Craigan C, Pamir N, Fazio S. Use of commercial genetic testing to help reclassify LDL receptor variants in clinical practice: A case report. J Clin Lipidol 2021;15:447-50. [PMID: 33992589 DOI: 10.1016/j.jacl.2021.04.007] [Reference Citation Analysis]
24 Øyri LKL, Hansson P, Bogsrud MP, Narverud I, Florholmen G, Leder L, Byfuglien MG, Veierød MB, Ulven SM, Holven KB. Delayed postprandial TAG peak after intake of SFA compared with PUFA in subjects with and without familial hypercholesterolaemia: a randomised controlled trial. Br J Nutr 2018;119:1142-50. [PMID: 29759104 DOI: 10.1017/S0007114518000673] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.7] [Reference Citation Analysis]
25 Li S, Wu N, Zhu C, Zhang Y, Guo Y, Gao Y, Li X, Qing P, Cui C, Xu R, Sun J, Liu G, Dong Q, Li J. Significance of lipoprotein(a) levels in familial hypercholesterolemia and coronary artery disease. Atherosclerosis 2017;260:67-74. [DOI: 10.1016/j.atherosclerosis.2017.03.021] [Cited by in Crossref: 40] [Cited by in F6Publishing: 38] [Article Influence: 8.0] [Reference Citation Analysis]
26 Izar MCO, Giraldez VZR, Bertolami A, Santos Filho RDD, Lottenberg AM, Assad MHV, Saraiva JFK, Chacra APM, Martinez TLR, Bahia LR, Fonseca FAH, Faludi AA, Sposito AC, Chagas ACP, Jannes CE, Amaral CK, Araújo DB, Cintra DE, Coutinho EDR, Cesena F, Xavier HT, Mota ICP, Giuliano ICB, Faria Neto JR, Kato JT, Bertolami MC, Miname MH, Castelo MHCG, Lavrador MSF, Machado RM, Souza PG, Alves RJ, Machado VA, Salgado Filho W. Update of the Brazilian Guideline for Familial Hypercholesterolemia - 2021. Arq Bras Cardiol 2021;117:782-844. [PMID: 34709306 DOI: 10.36660/abc.20210788] [Reference Citation Analysis]
27 Andersen LH, Miserez AR, Ahmad Z, Andersen RL. Familial defective apolipoprotein B-100: A review. Journal of Clinical Lipidology 2016;10:1297-302. [DOI: 10.1016/j.jacl.2016.09.009] [Cited by in Crossref: 38] [Cited by in F6Publishing: 33] [Article Influence: 6.3] [Reference Citation Analysis]
28 Kamar A, Khalil A, Nemer G. The Digenic Causality in Familial Hypercholesterolemia: Revising the Genotype-Phenotype Correlations of the Disease. Front Genet 2020;11:572045. [PMID: 33519890 DOI: 10.3389/fgene.2020.572045] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
29 Elkins JC, Fruh S. Early diagnosis and treatment of familial hypercholesterolemia. Nurse Pract 2019;44:18-24. [PMID: 30614895 DOI: 10.1097/01.NPR.0000552677.31028.57] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
30 Jia X, Al Rifai M, Liu J, Agarwala A, Gulati M, Virani SS. Highlights of Studies in Cardiovascular Disease Prevention Presented at the 2020 American College of Cardiology Annual Scientific Session. Curr Atheroscler Rep 2020;22:32. [PMID: 32556778 DOI: 10.1007/s11883-020-00856-6] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
31 Ito MK, Santos RD. PCSK9 Inhibition With Monoclonal Antibodies: Modern Management of Hypercholesterolemia. J Clin Pharmacol 2017;57:7-32. [PMID: 27195910 DOI: 10.1002/jcph.766] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 3.2] [Reference Citation Analysis]
32 Santos RD, Gidding SS, Hegele RA, Cuchel MA, Barter PJ, Watts GF, Baum SJ, Catapano AL, Chapman MJ, Defesche JC, Folco E, Freiberger T, Genest J, Hovingh GK, Harada-shiba M, Humphries SE, Jackson AS, Mata P, Moriarty PM, Raal FJ, Al-rasadi K, Ray KK, Reiner Z, Sijbrands EJG, Yamashita S. Defining severe familial hypercholesterolaemia and the implications for clinical management: a consensus statement from the International Atherosclerosis Society Severe Familial Hypercholesterolemia Panel. The Lancet Diabetes & Endocrinology 2016;4:850-61. [DOI: 10.1016/s2213-8587(16)30041-9] [Cited by in Crossref: 191] [Cited by in F6Publishing: 52] [Article Influence: 31.8] [Reference Citation Analysis]
33 Jia X, Al Rifai M, Hussain A, Martin S, Agarwala A, Virani SS. Highlights from Studies in Cardiovascular Disease Prevention Presented at the Digital 2020 European Society of Cardiology Congress: Prevention Is Alive and Well. Curr Atheroscler Rep 2020;22:72. [PMID: 33009957 DOI: 10.1007/s11883-020-00895-z] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
34 Wand H, Sturm AC, Erby L, Kindt I, Klein WMP. Genetic testing preferences and intentions in patients with clinically diagnosed familial hypercholesterolemia. J Genet Couns 2020;29:919-27. [PMID: 31769116 DOI: 10.1002/jgc4.1194] [Reference Citation Analysis]
35 Ryan A, Byrne CD. Importance of early recognition of heterozygous familial hypercholesterolaemia: . Current Opinion in Lipidology 2015;26:298-303. [DOI: 10.1097/mol.0000000000000196] [Cited by in Crossref: 7] [Article Influence: 1.0] [Reference Citation Analysis]
36 Rogers CS. Genetically engineered livestock for biomedical models. Transgenic Res. 2016;25:345-359. [PMID: 26820410 DOI: 10.1007/s11248-016-9928-6] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
37 Ben Djoudi Ouadda A, Gauthier MS, Susan-Resiga D, Girard E, Essalmani R, Black M, Marcinkiewicz J, Forget D, Hamelin J, Evagelidis A, Ly K, Day R, Galarneau L, Corbin F, Coulombe B, Çaku A, Tagliabracci VS, Seidah NG. Ser-Phosphorylation of PCSK9 (Proprotein Convertase Subtilisin-Kexin 9) by Fam20C (Family With Sequence Similarity 20, Member C) Kinase Enhances Its Ability to Degrade the LDLR (Low-Density Lipoprotein Receptor). Arterioscler Thromb Vasc Biol 2019;39:1996-2013. [PMID: 31553664 DOI: 10.1161/ATVBAHA.119.313247] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
38 Haber SL, Fairman KA, Sclar DA. Principles in the Evaluation of Systematic Reviews. Pharmacotherapy 2015;35:1077-87. [PMID: 26598099 DOI: 10.1002/phar.1657] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
39 Sun D, Li S, Zhao X, Wu NQ, Zhu CG, Guo YL, Gao Y, Qing P, Cui CJ, Liu G, Sun J, Dong Q, Li JJ. Association between lipoprotein (a) and proprotein convertase substilisin/kexin type 9 in patients with heterozygous familial hypercholesterolemia: A case-control study. Metabolism 2018;79:33-41. [PMID: 29129821 DOI: 10.1016/j.metabol.2017.11.004] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.4] [Reference Citation Analysis]
40 Li JJ, Li S, Zhu CG, Wu NQ, Zhang Y, Guo YL, Gao Y, Li XL, Qing P, Cui CJ, Xu RX, Jiang ZW, Sun J, Liu G, Dong Q. Familial Hypercholesterolemia Phenotype in Chinese Patients Undergoing Coronary Angiography. Arterioscler Thromb Vasc Biol 2017;37:570-9. [PMID: 27932355 DOI: 10.1161/ATVBAHA.116.308456] [Cited by in Crossref: 32] [Cited by in F6Publishing: 16] [Article Influence: 5.3] [Reference Citation Analysis]
41 Giammanco A, Spina R, Fayer F, Barbagallo CM, Noto D, Cefalù AB, Averna MR. Lack of phenotypic additive effect of familial defective apolipoprotein B3531 in familial hypercholesterolaemia. Intern Med J 2021;51:585-90. [PMID: 33890362 DOI: 10.1111/imj.15275] [Reference Citation Analysis]
42 Silventoinen K, Hjelmborg J, Möller S, Ripatti S, Skythe A, Tikkanen E, Pedersen NL, Magnusson PK, Christensen K, Kaprio J. Family aggregation of cardiovascular disease mortality: a register-based prospective study of pooled Nordic twin cohorts. International Journal of Epidemiology 2017;46:1223-9. [DOI: 10.1093/ije/dyx012] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
43 Silva PRS, Jannes CE, Oliveira TGM, Gómez LMG, Krieger JE, Santos RD, Pereira AC. Predictors of Family Enrollment in a Genetic Cascade Screening Program for Familial Hypercholesterolemia. Arq Bras Cardiol 2018;111:578-84. [PMID: 30156605 DOI: 10.5935/abc.20180156] [Reference Citation Analysis]
44 Zheng H, Zeng Z, Wen H, Wang P, Huang C, Huang P, Chen Q, Gong D, Qiu X. Application of Genome-Wide Association Studies in Coronary Artery Disease. Curr Pharm Des 2019;25:4274-86. [PMID: 31692429 DOI: 10.2174/1381612825666191105125148] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
45 Shakhtshneider E, Ivanoshchuk D, Timoshchenko O, Orlov P, Semaev S, Valeev E, Goonko A, Ladygina N, Voevoda M. Analysis of Rare Variants in Genes Related to Lipid Metabolism in Patients with Familial Hypercholesterolemia in Western Siberia (Russia). J Pers Med 2021;11:1232. [PMID: 34834584 DOI: 10.3390/jpm11111232] [Reference Citation Analysis]
46 Guarnieri F, Kulp JL Jr, Kulp JL 3rd, Cloudsdale IS. Fragment-based design of small molecule PCSK9 inhibitors using simulated annealing of chemical potential simulations. PLoS One 2019;14:e0225780. [PMID: 31805108 DOI: 10.1371/journal.pone.0225780] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]